Merck, Moderna detail potential skin cancer vaccine progress.
That combination was compared with Keytruda alone in a mid-stage clinical trial of 157 patients. Patients received either the combination or Keytruda after surgery to remove the tumors.
The patient group that took the potential vaccine and Keytruda saw a 44% reduction in the risk of death or the cancer returning, the companies said.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Leer más »
Stocks making the biggest moves in the premarket: Oracle, Boeing, Moderna and moreThe stocks making the biggest moves in premarket trading include Oracle, Boeing, Moderna, and more.
Leer más »
Experimental mRNA cancer vaccine with immunotherapy reduces risk of melanoma returning, preliminary study finds | CNNAn experimental personalized mRNA vaccine in combination with the immunotherapy Keytruda reduced the risk of recurrence or death from melanoma in patients who had already had surgery, Moderna and Merck said Tuesday.
Leer más »
Moderna’s mRNA Cancer Vaccine Shows Promise in Preliminary StudyA customized Moderna vaccine combined with a Merck immunotherapy helped ward off the recurrence of skin cancer in people in a midstage trial
Leer más »
New Gen Talent, Animation, IPs Set to Power Up Malaga’s Spanish Screenings ContentAlready part of the biggest national film-TV industry platform in Spain’s history, Malaga Festival’s massive Spanish Screenings Content are set to build yet further in 2023, homing in on poten…
Leer más »
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Leer más »